Gilles Bru-Mercier

This inventor holds 5 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignees: National Institute of Health and Medical Research, Assistance Publique-Hopitaux De Paris, Centre National De La Recherche Scientifique. Active years: 2020-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gilles Bru-Mercier. Retrieved from https://idiyas.com/inventor/gilles-bru-mercier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)

Location History:

Pessac, FR (2020)
Le Plessis Robinson, FR (2020 - 2024)

Company Filing History:

5 out of 1,853

National Institute of Health and Medical Research

patents

4 out of 331

Assistance Publique-Hopitaux De Paris

patents

4 out of 5,383

Centre National De La Recherche Scientifique

patents

4. 3 out of 3

Hopital Marie Lannelongue

Université Paris-Saclay

patents

where one patent can have more than one assignee

Years Active: 2020-2025

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12274694 - Dizocilpine derivatives as peripheral NMDA receptor antagonists (2025-04-14),

2. 11944616 - Dizocilpine derivatives as peripheral NMDA receptor antagonists (2024-04-02),

3. 11376245 - Dizocilpine derivatives as peripheral NMDA receptor antagonists (2022-07-05),

4. 10583171 - NMDAR antagonists for the treatment of diseases associated with angiogenesis (2020-03-10),

5. 10538482 - Adamantane and memantine derivatives as peripheral NMDA receptor antagonists (2020-01-21),

Title: Gilles Bru-Mercier: Innovator in NMDA Receptor Antagonists

Introduction

Gilles Bru-Mercier is a notable inventor based in Le Plessis-Robinson, France. He has made significant contributions to the field of pharmacology, particularly in the development of NMDA receptor antagonists. With a total of 5 patents to his name, Bru-Mercier's work has implications for various therapeutic applications.

Latest Patents

Among his latest patents, Bru-Mercier has focused on dizocilpine derivatives as peripheral NMDA receptor antagonists. The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists. This innovative approach aims to enhance the efficacy of treatments targeting neurological disorders.

Career Highlights

Throughout his career, Gilles Bru-Mercier has worked with prestigious institutions such as the Institut National de la Santé et de la Recherche Médicale and the Centre National de la Recherche Scientifique. His experience in these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

Some of his notable coworkers include Sylvia Cohen-Kaminsky and Marc Humbert. Their collaborative efforts have further enriched the research landscape in which Bru-Mercier operates.

Conclusion

Gilles Bru-Mercier stands out as an influential inventor in the realm of NMDA receptor antagonists. His innovative patents and collaborations reflect his commitment to advancing medical science.

Profile summary based on public USPTO records.